Cargando…
Telithromycin: The Perils of Hasty Adoption and Persistence of Off-Label Prescribing
BACKGROUND: Telithromycin (Ketek) was approved in April 2004 for the treatment of acute bacterial exacerbations of chronic bronchitis (ABECB), bacterial sinusitis, and community-acquired pneumonia. The approval of telithromycin was controversial due to trial irregularities, noninferiority study desi...
Autores principales: | Gleason, Patrick P., Walters, Carol, Heaton, Alan H., Schafer, Jeremy A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437775/ https://www.ncbi.nlm.nih.gov/pubmed/17605513 http://dx.doi.org/10.18553/jmcp.2007.13.5.420 |
Ejemplares similares
-
Hasty Conclusions
Publicado: (1905) -
Thomas Hastie Bryce
Publicado: (1946) -
Telithromycin-resistant Streptococcus pneumoniae
por: Goldstein, Fred W., et al.
Publicado: (2005) -
Inhibition by telithromycin of systemic and respiratory inflammation induced by endotoxin in mice
por: Leiva, Magdalena, et al.
Publicado: (2007) -
The perils of a persistent cough
por: Fox, Natalya, et al.
Publicado: (2020)